NCT06489340: A trial that was reported late by ZyVersa Therapeutics, Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT06489340 |
|---|---|
| Title | A Phase 2a Open Label Study to Evaluate Cholesterol Efflux Mediator™ VAR200: 2- Hydroxypropyl-β-cyclodextrin (2-HPβCD) in Subjects With Type 2 Diabetic Kidney Disease (DKD) |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 11, 2025 |
| Completion date | Aug. 11, 2026 |
| Required reporting date | Aug. 11, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 2, 2025 |
| Days late | None |